295 related articles for article (PubMed ID: 27917404)
1. The Emerging Role of Cdk5 in Cancer.
Pozo K; Bibb JA
Trends Cancer; 2016 Oct; 2(10):606-618. PubMed ID: 27917404
[TBL] [Abstract][Full Text] [Related]
2. Cdk5 links with DNA damage response and cancer.
Liu W; Li J; Song YS; Li Y; Jia YH; Zhao HD
Mol Cancer; 2017 Mar; 16(1):60. PubMed ID: 28288624
[TBL] [Abstract][Full Text] [Related]
3. A kinase of many talents: non-neuronal functions of CDK5 in development and disease.
Sharma S; Sicinski P
Open Biol; 2020 Jan; 10(1):190287. PubMed ID: 31910742
[TBL] [Abstract][Full Text] [Related]
4. CDK5 Activates Hippo Signaling to Confer Resistance to Radiation Therapy Via Upregulating TAZ in Lung Cancer.
Zeng Y; Liu Q; Wang Y; Tian C; Yang Q; Zhao Y; Liu L; Wu G; Xu S
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):758-769. PubMed ID: 32407930
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.
Pozo K; Hillmann A; Augustyn A; Plattner F; Hai T; Singh T; Ramezani S; Sun X; Pfragner R; Minna JD; Cote GJ; Chen H; Bibb JA; Nwariaku FE
Oncotarget; 2015 May; 6(14):12080-93. PubMed ID: 25900242
[TBL] [Abstract][Full Text] [Related]
6. CDK5 in oncology: recent advances and future prospects.
Lenjisa JL; Tadesse S; Khair NZ; Kumarasiri M; Yu M; Albrecht H; Milne R; Wang S
Future Med Chem; 2017 Oct; 9(16):1939-1962. PubMed ID: 29076761
[TBL] [Abstract][Full Text] [Related]
7. Biological functions of CDK5 and potential CDK5 targeted clinical treatments.
Shupp A; Casimiro MC; Pestell RG
Oncotarget; 2017 Mar; 8(10):17373-17382. PubMed ID: 28077789
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells.
Lindqvist J; Imanishi SY; Torvaldson E; Malinen M; Remes M; Örn F; Palvimo JJ; Eriksson JE
Mol Biol Cell; 2015 Jun; 26(11):1971-84. PubMed ID: 25851605
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.
Herzog J; Ehrlich SM; Pfitzer L; Liebl J; Fröhlich T; Arnold GJ; Mikulits W; Haider C; Vollmar AM; Zahler S
Oncotarget; 2016 May; 7(19):27108-21. PubMed ID: 27027353
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cyclin-dependent kinase 5 in metastatic melanoma.
Sharma S; Zhang T; Michowski W; Rebecca VW; Xiao M; Ferretti R; Suski JM; Bronson RT; Paulo JA; Frederick D; Fassl A; Boland GM; Geng Y; Lees JA; Medema RH; Herlyn M; Gygi SP; Sicinski P
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8001-8012. PubMed ID: 32193336
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
12. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Ehrlich SM; Liebl J; Ardelt MA; Lehr T; De Toni EN; Mayr D; Brandl L; Kirchner T; Zahler S; Gerbes AL; Vollmar AM
J Hepatol; 2015 Jul; 63(1):102-13. PubMed ID: 25660209
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.
Merk H; Zhang S; Lehr T; Müller C; Ulrich M; Bibb JA; Adams RH; Bracher F; Zahler S; Vollmar AM; Liebl J
Oncotarget; 2016 Feb; 7(5):6088-104. PubMed ID: 26755662
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Strock CJ; Park JI; Nakakura EK; Bova GS; Isaacs JT; Ball DW; Nelkin BD
Cancer Res; 2006 Aug; 66(15):7509-15. PubMed ID: 16885348
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.
Hsu FN; Chen MC; Lin KC; Peng YT; Li PC; Lin E; Chiang MC; Hsieh JT; Lin H
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E975-86. PubMed ID: 23941877
[TBL] [Abstract][Full Text] [Related]
16. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.
Ren Y; Zhou X; Yang JJ; Liu X; Zhao XH; Wang QX; Han L; Song X; Zhu ZY; Tian WP; Zhang L; Mei M; Kang CS
Cancer Lett; 2015 Jul; 362(2):174-82. PubMed ID: 25827073
[TBL] [Abstract][Full Text] [Related]
17. Phosphoprotein-based biomarkers as predictors for cancer therapy.
Carter AM; Tan C; Pozo K; Telange R; Molinaro R; Guo A; De Rosa E; Martinez JO; Zhang S; Kumar N; Takahashi M; Wiederhold T; Ghayee HK; Oltmann SC; Pacak K; Woltering EA; Hatanpaa KJ; Nwariaku FE; Grubbs EG; Gill AJ; Robinson B; Gillardon F; Reddy S; Jaskula-Sztul R; Mobley JA; Mukhtar MS; Tasciotti E; Chen H; Bibb JA
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18401-18411. PubMed ID: 32690709
[TBL] [Abstract][Full Text] [Related]
18. Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5.
Arif A
Biochem Pharmacol; 2012 Oct; 84(8):985-93. PubMed ID: 22795893
[TBL] [Abstract][Full Text] [Related]
19. Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors.
Di Stefano M; Galati S; Ortore G; Caligiuri I; Rizzolio F; Ceni C; Bertini S; Bononi G; Granchi C; Macchia M; Poli G; Tuccinardi T
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142566
[TBL] [Abstract][Full Text] [Related]
20. Cdk5: multitasking between physiological and pathological conditions.
Lopes JP; Agostinho P
Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
